All data are based on the daily closing price as of November 1, 2024

SK Bioscience Wins First Indonesia Approval for Cell-Based Flu Shot

Cell-cultured vaccine eliminates need for antibiotics and preservatives in production process
South Korea
s 302440.KO Mid and Small Cap 2000
Share this on

SK Bioscience secured regulatory clearance to sell its cell-cultured influenza vaccine in Indonesia, marking the first approval of a domestically developed flu shot in Southeast Asia’s largest economy.

The Korean vaccine maker’s SKYCellflu Quadrivalent received the green light from Indonesia’s food and drug regulator BPOM, the company said in a statement. The approval positions SK Bioscience to tap into a market projected to reach $69.1 million by 2030, up from $38.5 million in 2022, according to research firm Innsight10.

Indonesia presents unique opportunities for vaccine manufacturers due to its geography spanning both hemispheres, requiring year-round flu shot supplies. The company expects fast-track approval for its Southern Hemisphere variant following this authorization.

SK Bioscience claims its cell-based production method reduces mutation risks compared to traditional egg-based vaccines, citing internal research presented at a 2019 symposium. The vaccine has already gained approvals across Asia and Chile.

CEO Ahn Jae-yong indicated the Indonesian approval supports the company’s broader strategy to expand its global footprint beyond its home market of South Korea.

Share this on
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top